The European Commission has announced the opening of an antitrust investigation into French pharmaceutical giant Sanofi. The probe focuses on Sanofi's marketing practices for its enhanced flu vaccine, Efluelda, which is designed to provide greater protection for individuals over 60. The Commission is concerned that Sanofi may have pursued a misleading communication campaign to disparage a competing vaccine, Fluad, marketed by Australian company CSL Seqirus.
Concerns Over Misleading Campaign
According to a statement from the Commission, the investigation centers on allegations that Sanofi's campaign portrayed Fluad as inferior to Efluelda, contrary to national vaccination recommendations in several EU member states. The campaign primarily targeted healthcare professionals in Germany and France, where Sanofi is considered to hold a dominant position in the market.
Sanofi's Response
Sanofi has denied any wrongdoing, asserting that it has acted in full compliance with all applicable laws and regulations, including competition rules. A company spokeswoman described the EU inquiry as 'a procedural step' that 'does not in any way prejudge the outcome of the investigation.' Sanofi remains committed to fair competition and maintaining patient access to innovative vaccines.
Potential Consequences
If the alleged anticompetitive practices are confirmed, the Commission could impose a penalty on Sanofi for abuse of a dominant position, potentially in the form of a fine. As part of the proceedings, Sanofi may also offer commitments to address the Commission's concerns. Flu vaccines are a significant business for Sanofi, with its products widely administered as part of annual national vaccination campaigns, particularly in France.
